FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA D.I.S.C.O. Burst Edition: FDA approval of Ojemda (tovorafenib) for relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation

Listen Later
Listen to a soundcast of the April 23, 2024, FDA approval of Ojemda (tovorafenib) for relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
...more
View all episodesView all episodes
Download on the App Store
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)By U.S. Food and Drug Administration, Center for Drug Evaluation and Research
  • 4.4
  • 4.4
  • 4.4
  • 4.4
  • 4.4

4.4

14 ratings

More shows like FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

View all
FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research

FDA Drug Safety Podcasts

5 Listeners

FDA Guidance Recap Podcast by U.S. Food and Drug Administration

FDA Guidance Recap Podcast

8 Listeners